生物医药ETF（512290）涨超1.2%，医保稳健运行支撑行业支付环境

Group 1 - The core viewpoint is that the national medical insurance fund in China is operating safely and steadily in 2024, with both total income and expenditure showing a year-on-year growth trend [1] - The cumulative balance of employee medical insurance and urban-rural resident medical insurance reached 4.49 trillion and 818.3 billion respectively, indicating overall stable fund operations [1] - The insured population remains stable at over 95%, with employee medical insurance participants increasing by 2.3%, income growing by 3.5%, and expenditure rising by 7.6% [1] Group 2 - Resident medical insurance income increased by 5.78%, while expenditure grew by 1.9%, reflecting a healthy financial environment for the sector [1] - The coordinated development of the "three medicines" (medical, medicine, and health) has significantly improved governance, providing a stable payment environment for the biopharmaceutical industry [1] - There is a noticeable trend of innovation and internationalization in the industry, with a focus on innovative drugs and medical consumption opportunities, as well as breakthroughs in technologies like restructured collagen new materials [1] Group 3 - The biopharmaceutical ETF tracks the CS Biomedicine Index, which is compiled by China Securities Index Co., Ltd., selecting listed companies in biotechnology, medical devices, and medical services to reflect the overall performance of the biopharmaceutical sector [1] - The index is characterized by strong industry representation and growth potential, effectively reflecting the development trends of the biopharmaceutical industry [1] - Investors without stock accounts can consider the Guotai CSI Biopharmaceutical ETF Connect A (006756) and Connect C (006757) [1]